Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | PNMT | P11086 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1194386 | 0.84 | ALDH1A1 (0.56) | ALDH1A1KDM4EMAPTHPGDSMN1; SMN2 | |
| SCHEMBL5963 | 0.82 | ALDH1A1 (0.55) | ALDH1A1KDM4EMAPTHPGDSMN1; SMN2 | |
| SCHEMBL513341 | 0.80 | ALDH1A1 (0.53) | ALDH1A1KDM4EMAPTHPGDSMN1; SMN2 | |
| SCHEMBL513342 | 0.80 | ALDH1A1 (0.53) | ALDH1A1KDM4EMAPTHPGDSMN1; SMN2 | |
| SCHEMBL30207794 | 0.80 | ALDH1A1 (0.53) | ALDH1A1KDM4EMAPTHPGDSMN1; SMN2 | |
| SCHEMBL24011712 | 0.80 | ALDH1A1 (0.53) | ALDH1A1KDM4EMAPTHPGDSMN1; SMN2 | |
| SCHEMBL496738 | 0.80 | ALDH1A1 (0.53) | ALDH1A1KDM4EMAPTHPGDSMN1; SMN2 | |
| SCHEMBL1645990 | 0.80 | ALDH1A1 (0.53) | ALDH1A1KDM4EMAPTHPGDSMN1; SMN2 | |
| SCHEMBL14378218 | 0.78 | KMT2A (0.53) | ALDH1A1KDM4EMAPTHPGDSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL28130066 | 0.78 | ALDH1A1 (0.51) | ALDH1A1KDM4EMAPTHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492390-B2 | Synthesis of locked nucleic acid derivatives | SANTARIS PHARMA A/S (DK) | 2013-07-23 | — | — | US | claimed |
| US-8084458-B2 | Synthesis of locked nucleic acid derivatives | SANTARIS PHARMA A/S (DK) | 2011-12-27 | — | — | US | claimed |
| US-20100216983-A1 | SYNTHESIS OF LOCKED NUCLEIC ACID DERIVATIVES | SANTARIS PHARMA A/S, a Denmark corporation | 2010-08-26 | — | — | US | claimed |
| US-7569575-B2 | Formed via intermediates which are reactive with nucleophiles | SANTARIS PHARMA A/S (DK) | 2009-08-04 | — | — | US | claimed |
| EP-1501848-B1 | SYNTHESIS OF LOCKED NUCLEIC ACID DERIVATIVES | SANTARIS PHARMA AS (DK) | 2007-08-08 | — | — | EP | claimed |
| EP-1163250-B1 | IMPROVED SYNTHESIS OF ¬2.2.1|BICYCLO NUCLEOSIDES | EXIQON AS (DK) | 2006-07-12 | — | — | EP | claimed |
| EP-1501848-A1 | SYNTHESIS OF LOCKED NUCLEIC ACID DERIVATIVES | Santaris Pharma A/S (DK) | 2005-02-02 | — | — | EP | claimed |
| US-20040014959-A1 | Synthesis of locked nucleic acid derivatives | SANTARIS PHARMA A/S (DK) | 2004-01-22 | — | — | US | claimed |
| WO-2003095467-A1 | SYNTHESIS OF LOCKED NUCLEIC ACID DERIVATIVES | SANTARIS PHARMA A/S (DK) | 2003-11-20 | — | — | WO | claimed |
| US-8492390-B2 | Synthesis of locked nucleic acid derivatives | SANTARIS PHARMA A/S (DK) | 2013-07-23 | — | — | US | disclosed |
| US-20120165514-A1 | SYNTHESIS OF LOCKED NUCLEIC ACID DERIVATIVES | SANTARIS PHARMA A/S (DK) | 2012-06-28 | — | — | US | disclosed |
| US-8084458-B2 | Synthesis of locked nucleic acid derivatives | SANTARIS PHARMA A/S (DK) | 2011-12-27 | — | — | US | disclosed |
| US-20100216983-A1 | SYNTHESIS OF LOCKED NUCLEIC ACID DERIVATIVES | SANTARIS PHARMA A/S, a Denmark corporation | 2010-08-26 | — | — | US | disclosed |
| US-7569575-B2 | Formed via intermediates which are reactive with nucleophiles | SANTARIS PHARMA A/S (DK) | 2009-08-04 | — | — | US | disclosed |
| EP-1501848-B1 | SYNTHESIS OF LOCKED NUCLEIC ACID DERIVATIVES | SANTARIS PHARMA AS (DK) | 2007-08-08 | — | — | EP | disclosed |
| EP-1163250-B1 | IMPROVED SYNTHESIS OF ¬2.2.1|BICYCLO NUCLEOSIDES | EXIQON AS (DK) | 2006-07-12 | — | — | EP | disclosed |
| EP-1501848-A1 | SYNTHESIS OF LOCKED NUCLEIC ACID DERIVATIVES | Santaris Pharma A/S (DK) | 2005-02-02 | — | — | EP | disclosed |
| US-20040014959-A1 | Synthesis of locked nucleic acid derivatives | SANTARIS PHARMA A/S (DK) | 2004-01-22 | — | — | US | disclosed |
| WO-2003095467-A1 | SYNTHESIS OF LOCKED NUCLEIC ACID DERIVATIVES | SANTARIS PHARMA A/S (DK) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216983-A1 | SYNTHESIS OF LOCKED NUCLEIC ACID DERIVATIVES | RNGTT, NSUN3, NSUN2 | ALDH1A1 1716/4885KDM4E 2204/4885MAPT 2218/4885 |
| US-20120165514-A1 | SYNTHESIS OF LOCKED NUCLEIC ACID DERIVATIVES | RNGTT, NSUN3, NSUN2 | ALDH1A1 1716/4885KDM4E 2204/4885MAPT 2218/4885 |
| US-20040014959-A1 | Synthesis of locked nucleic acid derivatives | NSUN3, RNGTT, NSUN2 | ALDH1A1 1589/4885KDM4E 2081/4885MAPT 2369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.